Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Gastric Cancer. 2015 Nov 18;19(4):1066–1079. doi: 10.1007/s10120-015-0566-0

Figure 4. Her2 IHC correlations with FISH assay or SRM.

Figure 4

Correlation of Her2 IHC to (A) FISH GCN in 42 GEC tumors (r2=0.1959), (B) HER2/CEP17 ratio in n=52 GEC tumors (r2=0.1242) (52 cases with IHC results had absolute FISH ratio results); and (C) Her2-SRM (amol/μg) in 122 GEC tumors (r2=0.0355). (D) IHC compared to Her2-SRM with inset 2X2 table; and (E) three-way comparison of Her2-IHC, Her2-SRM and HER2/CEP17 ratio by FISH in 51 GEC tumors where all three values were available. Inset tables demonstrate the comparison of the lower boundary for each assay (left, IHC2+ versus SRM 450amol/ug) and IHC2+ versus FISH (right). Red bar-SRM, green bar-IHC, and black dot-HER2/CEP17 ratio by FISH. Inset tables assess sensitivity/specificity of IHC assuming SRM (D,E) and FISH (B,E) as the comparative standards.